Literature DB >> 25517416

Hormone and Drug-Mediated Modulation of Glucose Metabolism in a Microscale Model of the Human Liver.

Matthew D Davidson1, Michael Lehrer2, Salman R Khetani1,3.   

Abstract

Due to its central role in glucose homeostasis, the liver is an important target for drug development efforts for type 2 diabetes mellitus (T2DM). Significant differences across species in liver metabolism necessitate supplementation of animal data with assays designed to assess human-relevant responses. However, isolated primary human hepatocytes (PHHs) display a rapid decline in phenotypic functions in conventional monolayer formats. Cocultivation of PHHs with specific stromal cells, especially in micropatterned configurations, can stabilize some liver functions for ~4 weeks in vitro. However, it remains unclear whether coculture approaches can stabilize glucose metabolism that can be modulated with hormones in PHHs. Thus, in this study, we compared commonly employed conventional culture formats and previously developed micropatterned cocultures (MPCCs) of cryopreserved PHHs and stromal fibroblasts for mRNA expression of key glucose metabolism genes (i.e., phosphoenolpyruvate carboxykinase-1 [PCK1]) and sensitivity of gluconeogenesis to prototypical hormones, insulin and glucagon. We found that only MPCCs displayed high expression of all transcripts tested for at least 2 weeks and robust gluconeogenesis with responsiveness to hormones for at least 3 weeks in vitro. Furthermore, MPCCs displayed glycogen storage and lysis, which could be modulated with hormones under the appropriate feeding and fasting states, respectively. Finally, we utilized MPCCs in proof-of-concept experiments where we tested gluconeogenesis inhibitors and evaluated the effects of stimulation with high levels of glucose as in T2DM. Gluconeogenesis in MPCCs was decreased after stimulation with drugs (i.e., metformin) and the PHHs accumulated significant amount of lipids following incubation with excess glucose (i.e., 340% in 50 mM glucose relative to physiologic 5 mM glucose controls). In conclusion, MPCCs provide a platform to study glucose metabolism and hormonal responsiveness in cryopreserved PHHs from multiple donors for several weeks in vitro. This model is also useful to study the effects of drugs and overnutrition for applications in T2DM.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25517416      PMCID: PMC4499785          DOI: 10.1089/ten.TEC.2014.0512

Source DB:  PubMed          Journal:  Tissue Eng Part C Methods        ISSN: 1937-3384            Impact factor:   3.056


  45 in total

Review 1.  Effect of cell-cell interactions in preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells.

Authors:  S N Bhatia; U J Balis; M L Yarmush; M Toner
Journal:  FASEB J       Date:  1999-11       Impact factor: 5.191

Review 2.  Concordance of the toxicity of pharmaceuticals in humans and in animals.

Authors:  H Olson; G Betton; D Robinson; K Thomas; A Monro; G Kolaja; P Lilly; J Sanders; G Sipes; W Bracken; M Dorato; K Van Deun; P Smith; B Berger; A Heller
Journal:  Regul Toxicol Pharmacol       Date:  2000-08       Impact factor: 3.271

3.  A novel 3D liver organoid system for elucidation of hepatic glucose metabolism.

Authors:  Yanhua Lu; Guoliang Zhang; Chong Shen; Korkut Uygun; Martin L Yarmush; Qin Meng
Journal:  Biotechnol Bioeng       Date:  2011-10-19       Impact factor: 4.530

4.  Microscale culture of human liver cells for drug development.

Authors:  Salman R Khetani; Sangeeta N Bhatia
Journal:  Nat Biotechnol       Date:  2007-11-18       Impact factor: 54.908

Review 5.  ImageJ for microscopy.

Authors:  Tony J Collins
Journal:  Biotechniques       Date:  2007-07       Impact factor: 1.993

Review 6.  Mechanisms for insulin resistance: common threads and missing links.

Authors:  Varman T Samuel; Gerald I Shulman
Journal:  Cell       Date:  2012-03-02       Impact factor: 41.582

7.  Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.

Authors:  A J Sanyal; C Campbell-Sargent; F Mirshahi; W B Rizzo; M J Contos; R K Sterling; V A Luketic; M L Shiffman; J N Clore
Journal:  Gastroenterology       Date:  2001-04       Impact factor: 22.682

8.  Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction.

Authors:  Niresh Hariparsad; Brian A Carr; Raymond Evers; Xiaoyan Chu
Journal:  Drug Metab Dispos       Date:  2008-03-10       Impact factor: 3.922

Review 9.  Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice.

Authors:  Catherine Postic; Jean Girard
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

Review 10.  Management of type 2 diabetes: new and future developments in treatment.

Authors:  Abd A Tahrani; Clifford J Bailey; Stefano Del Prato; Anthony H Barnett
Journal:  Lancet       Date:  2011-06-24       Impact factor: 79.321

View more
  18 in total

1.  Advances in Engineered Human Liver Platforms for Drug Metabolism Studies.

Authors:  Gregory H Underhill; Salman R Khetani
Journal:  Drug Metab Dispos       Date:  2018-08-22       Impact factor: 3.922

2.  A polyelectrolyte multilayer platform for investigating growth factor delivery modes in human liver cultures.

Authors:  Christine Lin; Raimundo Romero; Lioudmila V Sorokina; Kimberly R Ballinger; Laura W Place; Matt J Kipper; Salman R Khetani
Journal:  J Biomed Mater Res A       Date:  2017-12-04       Impact factor: 4.396

Review 3.  Engineered Liver Platforms for Different Phases of Drug Development.

Authors:  Brenton R Ware; Salman R Khetani
Journal:  Trends Biotechnol       Date:  2016-09-02       Impact factor: 19.536

4.  Micropatterned Co-Cultures of Human Hepatocytes and Stromal Cells for the Assessment of Drug Clearance and Drug-Drug Interactions.

Authors:  Christine Lin; Salman R Khetani
Journal:  Curr Protoc Toxicol       Date:  2017-05-02

5.  miR-122 Release in Exosomes Precedes Overt Tolvaptan-Induced Necrosis in a Primary Human Hepatocyte Micropatterned Coculture Model.

Authors:  Merrie Mosedale; J Scott Eaddy; O Joseph Trask; Natalie S Holman; Kristina K Wolf; Edward LeCluyse; Brenton R Ware; Salman R Khetani; Jingtao Lu; William J Brock; Sharin E Roth; Paul B Watkins
Journal:  Toxicol Sci       Date:  2018-01-01       Impact factor: 4.849

Review 6.  Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research.

Authors:  Joost Willebrords; Isabel Veloso Alves Pereira; Michaël Maes; Sara Crespo Yanguas; Isabelle Colle; Bert Van Den Bossche; Tereza Cristina Da Silva; Cláudia Pinto Marques Souza de Oliveira; Wellington Andraus; Venâncio Avancini Alves; Bruno Cogliati; Mathieu Vinken
Journal:  Prog Lipid Res       Date:  2015-06-11       Impact factor: 16.195

7.  Physiologically inspired culture medium prolongs the lifetime and insulin sensitivity of human hepatocytes in micropatterned co-cultures.

Authors:  Matthew D Davidson; Joshua Pickrell; Salman R Khetani
Journal:  Toxicology       Date:  2020-12-24       Impact factor: 4.221

Review 8.  Human biomimetic liver microphysiology systems in drug development and precision medicine.

Authors:  Albert Gough; Alejandro Soto-Gutierrez; Lawrence Vernetti; Mo R Ebrahimkhani; Andrew M Stern; D Lansing Taylor
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-12-17       Impact factor: 73.082

9.  Micropatterned coculture of primary human hepatocytes and supportive cells for the study of hepatotropic pathogens.

Authors:  Sandra March; Vyas Ramanan; Kartik Trehan; Shengyong Ng; Ani Galstian; Nil Gural; Margaret A Scull; Amir Shlomai; Maria M Mota; Heather E Fleming; Salman R Khetani; Charles M Rice; Sangeeta N Bhatia
Journal:  Nat Protoc       Date:  2015-11-19       Impact factor: 13.491

10.  Long-term exposure to abnormal glucose levels alters drug metabolism pathways and insulin sensitivity in primary human hepatocytes.

Authors:  Matthew D Davidson; Kimberly R Ballinger; Salman R Khetani
Journal:  Sci Rep       Date:  2016-06-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.